Harwood Feffer LLP Announces Investigation of Cellular Biomedicine Group, Inc.
May 4, 2015
NEW YORK, May 4, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Cellular Biomedicine Group, Inc. ("CBMG" or the "Company") (NASDAQ: CBMG), concerning whether the board has breached its fiduciary duties to shareholders.
On April 7, 2015, an article was posted on SeekingAlpha.com reporting that CBMG has engaged in a scheme to defrau investors. According to the article, CBMG used undisclosed paid stock promoters and the Company's financial statements suffered from "multiple accounting and financial integrity issues" including material weaknesses to internal controls.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own CBMG shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
SOURCE Harwood Feffer LLP